Cargando…
Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine
The pathophysiological mechanisms of migraine transformation are debated. Modifications of plasma oxidative stress biomarkers have been described in chronic migraine. OnabotulintoxinA (BoNT/A) treatment, approved for chronic migraine prophylaxis, possibly reduces pain neurotransmitters release and o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832499/ https://www.ncbi.nlm.nih.gov/pubmed/31635021 http://dx.doi.org/10.3390/toxins11100608 |
_version_ | 1783466187152162816 |
---|---|
author | Dini, Elisa Mazzucchi, Sonia De Luca, Ciro Cafalli, Martina Chico, Lucia Lo Gerfo, Annalisa Siciliano, Gabriele Bonuccelli, Ubaldo Baldacci, Filippo Gori, Sara |
author_facet | Dini, Elisa Mazzucchi, Sonia De Luca, Ciro Cafalli, Martina Chico, Lucia Lo Gerfo, Annalisa Siciliano, Gabriele Bonuccelli, Ubaldo Baldacci, Filippo Gori, Sara |
author_sort | Dini, Elisa |
collection | PubMed |
description | The pathophysiological mechanisms of migraine transformation are debated. Modifications of plasma oxidative stress biomarkers have been described in chronic migraine. OnabotulintoxinA (BoNT/A) treatment, approved for chronic migraine prophylaxis, possibly reduces pain neurotransmitters release and oxidative stress products. Aims of our study were to investigate differences in the levels of selected plasmatic oxidative stress biomarkers (Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), Thiolic Groups (SH)) comparing chronic migraineurs (CM) and healthy controls (HC). We also explored possible clinical and biochemical modifications in the CM group after six months of treatment with BoNT/A. At the baseline, we found higher values of AOPP (p < 0.001), and lower values of SH (p < 0.001) and FRAP (p = 0.005) in the CM group. At the six-month follow-up we found a reduction of AOPP (p < 0.001) and an increase of FRAP (p < 0.001) and SH (p = 0.023) within the CM group. BoNT/A treatment improved migraine symptoms in the CM group. We confirmed previous reports of imbalanced antioxidant mechanisms in chronic migraine showing lower antioxidant capacities in patients than controls. BoNT/A improved the levels of plasma oxidative stress biomarkers and confirmed its role as an effective prophylactic treatment for CM. Other studies should investigate the potential antioxidant properties of BoNT/A treatment. |
format | Online Article Text |
id | pubmed-6832499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68324992019-11-25 Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine Dini, Elisa Mazzucchi, Sonia De Luca, Ciro Cafalli, Martina Chico, Lucia Lo Gerfo, Annalisa Siciliano, Gabriele Bonuccelli, Ubaldo Baldacci, Filippo Gori, Sara Toxins (Basel) Article The pathophysiological mechanisms of migraine transformation are debated. Modifications of plasma oxidative stress biomarkers have been described in chronic migraine. OnabotulintoxinA (BoNT/A) treatment, approved for chronic migraine prophylaxis, possibly reduces pain neurotransmitters release and oxidative stress products. Aims of our study were to investigate differences in the levels of selected plasmatic oxidative stress biomarkers (Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), Thiolic Groups (SH)) comparing chronic migraineurs (CM) and healthy controls (HC). We also explored possible clinical and biochemical modifications in the CM group after six months of treatment with BoNT/A. At the baseline, we found higher values of AOPP (p < 0.001), and lower values of SH (p < 0.001) and FRAP (p = 0.005) in the CM group. At the six-month follow-up we found a reduction of AOPP (p < 0.001) and an increase of FRAP (p < 0.001) and SH (p = 0.023) within the CM group. BoNT/A treatment improved migraine symptoms in the CM group. We confirmed previous reports of imbalanced antioxidant mechanisms in chronic migraine showing lower antioxidant capacities in patients than controls. BoNT/A improved the levels of plasma oxidative stress biomarkers and confirmed its role as an effective prophylactic treatment for CM. Other studies should investigate the potential antioxidant properties of BoNT/A treatment. MDPI 2019-10-19 /pmc/articles/PMC6832499/ /pubmed/31635021 http://dx.doi.org/10.3390/toxins11100608 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dini, Elisa Mazzucchi, Sonia De Luca, Ciro Cafalli, Martina Chico, Lucia Lo Gerfo, Annalisa Siciliano, Gabriele Bonuccelli, Ubaldo Baldacci, Filippo Gori, Sara Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine |
title | Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine |
title_full | Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine |
title_fullStr | Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine |
title_full_unstemmed | Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine |
title_short | Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine |
title_sort | plasma levels of oxidative stress markers, before and after bont/a treatment, in chronic migraine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832499/ https://www.ncbi.nlm.nih.gov/pubmed/31635021 http://dx.doi.org/10.3390/toxins11100608 |
work_keys_str_mv | AT dinielisa plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine AT mazzucchisonia plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine AT delucaciro plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine AT cafallimartina plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine AT chicolucia plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine AT logerfoannalisa plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine AT sicilianogabriele plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine AT bonuccelliubaldo plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine AT baldaccifilippo plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine AT gorisara plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine |